Andrei Ungureanu
University of Modena and Reggio Emilia · 30 works · 1,132 citations · h-index 9
Top works
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations
- Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
- RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
- VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
- Abstract GS01-01: Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL
- Systematic Life Cycle Environmental Impact Comparison of Alternative Synthetic Strategies for Ti3C2Tx MXene
- Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients
- A systematic review on life cycle assessment (LCA) of metal-organic frameworks (MOFs) and MXenes
- The Value of Staging Laparoscopy for Optimal Multidisciplinary Treatment in Patients with Gastric Cancer
- The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
- Sinonasal malignant melanoma
- Attitudes towards COVID‑19 vaccination in patients with cancer: A cross‑sectional study of 12 oncology centers
- Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
- Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2– mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC)
- Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
- Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience
- Safety and efficacy of pegfilgastim for the prophylaxis of chemotherapy-induced neutropenia: A prospective, observational, multicenter, single-arm study
- THE IMMUNOHISTOCHEMISTRY OF THE GASTRIC LYMPHOMAS
- Additional file 3: of Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations